An immunochemical test for fecal occult blood was developed for use in colon cancer screening. The test employs high titer monospecific antisera to intact human hemoglobin in a radial immunodiffusion assay. Patient smears on specially treated filter paper allow screening procedures similar to those using Hemoccult slides. Minimum detectible hemoglobin was 0.3 mg/gm stool, and no cross reactivity with dietary constituents, drugs, or chemicals occurred. The accession of 150 consecutive cases of colon-rectal carcinoma was accomplished from three community hospitals. In each instance, at least one preoperative fecal specimen was obtained for companion smear testing with immunochemical punch-disc and commercial Hemoccult slides. Twenty-nine percent of the cases were found not to be bleeding by either test. Occult bleeding was detected by Hemoccult in 40% of the cases, and occult bleeding was detected by immunochemical testing in 65% of the cases. A surprising discovery was that rectal lesions had a much lower rate of of positiuity with both tests (Hemoccult-29%, Immunochemical-50%) than other locations. These results suggest that immunochemical screening for occult blood loss will provide a higher rate of detection of colon cancer.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/1097-0142(19800315)45:5+<1099::aid-cncr2820451312>3.0.co;2-t | DOI Listing |
BMJ Open
January 2025
Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China
Objectives: To assess the therapeutic effects and safety of Tongxie Yaofang (TXYF) granules vs placebo as an alternative treatment for diarrhoea-predominant irritable bowel syndrome (IBS-D). We hypothesised that TXYF would improve clinical responses among patients with IBS-D.
Design: A randomised, double-blind, placebo-controlled, phase II, superiority trial.
Medicine (Baltimore)
January 2025
Department of Gastroenterology, The Affiliated People's Hospital of Ningbo University, Ningbo, China.
Rationale: Gastric antral vascular ectasia (GAVE) is a rare acquired lesion characterized by vascular dilation in the gastric antrum, frequently results in occult or overt gastrointestinal bleeding. Endoscopic intervention remains the cornerstone of therapy. Argon plasma coagulation was previously considered a first treatment option.
View Article and Find Full Text PDFBMC Microbiol
January 2025
Huzhou Central Hospital, Affiliated Central Hospital Huzhou University, No.1558 Sanhuan North Road, Wuxing District, Huzhou, Zhejiang Province, 313000, People's Republic of China.
Background: Gut microbes have been used to predict CRC risk. Fecal occult blood test (FOBT) has been recommended for population screening of CRC.
Objective: To analyze the effects of fecal occult blood test (FOBT) on gut microbes.
Clin Biochem
January 2025
Department of Gastrointestinal Surgery, Yongchuan Hospital of Chongqing Medical University, Yongchuan, Chongqing 402160, China. Electronic address:
Objective: To investigate the clinical significance of fecal Syndecan-2 (SDC2) gene methylation combined with blood tumor abnormal protein (TAP) detection for the diagnosis of colorectal cancer (CRC) and its precancerous lesions.
Methods: A retrospective study was conducted to collect patients diagnosed with CRC or colorectal adenoma (Ade) from March 2020 to March 2023, and healthy people (Nor) without any gastrointestinal diseases during the same period as the control group. All participants underwent the fecal SDC2 gene methylation test, blood TAP test and fecal occult blood test (FOBT).
JAMA Netw Open
January 2025
Fred Hutchinson Cancer Research Center, Hutchinson Institute for Cancer Outcomes Research and Biostatistics Program, Public Health Sciences Division, Seattle, Washington.
Importance: Several noninvasive tests for colorectal cancer screening are available, but their effectiveness in settings with low adherence to screening and follow-up colonoscopy is not well documented.
Objective: To assess the cost-effectiveness of and outcomes associated with noninvasive colorectal cancer screening strategies, including new blood-based tests, in a population with low adherence to screening and ongoing surveillance colonoscopy.
Design, Setting, And Participants: The validated microsimulation model used for the decision analytical modeling study projected screening outcomes from 2025 to 2124 for a simulated cohort of 10 million individuals aged 50 years in 2025 and representative of a predominantly Hispanic or Latino patient population served by a Federally Qualified Health Center in Southern California.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!